According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...
Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...
Eli Lilly and Company LLY announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival Novo Nordisk’s NVO Wegovy ... as seen in the chart below.
According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued sales growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback